Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jun 30:21:906-920.
doi: 10.17179/excli2022-5073. eCollection 2022.

Elevated risk of thrombotic manifestations of SARS-CoV-2 infection in cancer patients: A literature review

Annunziata Stefanile  1 , Maria Cellerino  2   3 , Tatiana Koudriavtseva  4
Affiliations
Review

Elevated risk of thrombotic manifestations of SARS-CoV-2 infection in cancer patients: A literature review

Annunziata Stefanile et al. EXCLI J. .

Abstract

Coronavirus disease 2019 (COVID-19) results in higher risks of hospitalization or death in older patients and those with multiple comorbidities, including malignancies. Patients with cancer have greater risks of COVID-19 onset and worse prognosis. This excess is mainly explained by thrombotic complications. Indeed, an imbalance in the equilibrium between clot formation and bleeding, increased activation of coagulation, and endothelial dysfunction characterize both COVID-19 patients and those with cancer. With this review, we provide a summary of the pathological mechanisms of coagulation and thrombotic manifestations in these patients and discuss the possible therapeutic implications of these phenomena.

Keywords: SARS-CoV-2, COVID-19; cancer; coagulation; thrombotic manifestations.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Mechanisms of thrombosis in SARS-CoV-2 infected patients with cancer: a synergic process
COVID-19: coronavirus disease 2019; TF: tissue factor; VWF: von Willebrand factor; IFN: interferon; NETs: neutrophil extracellular traps
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Ackermann M, Verleden SE, Kuehnel M, Haverich A, Welte T, Laenger F, et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. N Engl J Med. 2020;383:120–128. doi: 10.1056/NEJMoa2015432. - DOI - PMC - PubMed
    1. Adelborg K, Corraini P, Darvalics B, Frederiksen H, Ording A, Horváth-Puhó E, et al. Risk of thromboembolic and bleeding outcomes following hematological cancers: A Danish population-based cohort study. J Thromb Haemost. 2019;17:1305–1318. doi: 10.1111/jth.14475. - DOI - PubMed
    1. Ajona D, Pajares MJ, Corrales L, Perez-Gracia JL, Agorreta J, Lozano MD, et al. Investigation of complement activation product c4d as a diagnostic and prognostic biomarker for lung cancer. J Natl Cancer Inst. 2013;105:1385–1393. doi: 10.1093/jnci/djt205. - DOI - PMC - PubMed
    1. Artifoni M, Danic G, Gautier G, Gicquel P, Boutoille D, Raffi F, et al. Systematic assessment of venous thromboembolism in COVID-19 patients receiving thromboprophylaxis: incidence and role of D-dimer as predictive factors. J Thromb Thrombolysis. 2020;50:211–216. doi: 10.1007/s11239-020-02146-z. - DOI - PMC - PubMed
    1. Bauer AT, Gorzelanny C, Gebhardt C, Pantel K, Schneider SW. Interplay between coagulation and inflammation in cancer: Limitations and therapeutic opportunities. Cancer Treat Rev. 2022;102:102322. doi: 10.1016/j.ctrv.2021.102322. - DOI - PubMed

LinkOut - more resources